Loading clinical trials...
Loading clinical trials...
Intensive care unit-acquired weakness (ICU-AW) is the most common neuromuscular impairment in critically ill patients. It affects more than 50 % of patients in the intensive care and is related to man...
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Ain Shams University
NCT07167121 · ICU Acquired Weakness, Intensive Care Neuropathy
NCT06849765 · ICU Acquired Weakness (ICUAW)
NCT04922814 · COVID-19 Acute Respiratory Distress Syndrome, Sedation Complication, and more
NCT05326633 · Critical Illness, Sarcopenia, and more
NCT05048953 · ICU Acquired Weakness
Ain Shams University hospitals
Cairo, Abbaseya
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions